BRD9

Across TCGA pan-cancer cohorts, BRD9 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BRD9 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher BRD9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BRD9 expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

UCEC, GBM, and CCRCC are the cancer types where BRD9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Quartile	All	0.864	1.000	.017	14	view →
GBM	OS	Median	All	0.515	0.279	.008	12	view →
CCRCC	DFS	Median	IV	1.000	0.314	.017	6	view →
PDAC	OS	Quartile	II,III,IV	0.366	0.673	.022	5	view →
OV	DFS	Median	All	0.862	1.000	.036	4	view →
LSCC	DFS	Median	All	0.949	0.927	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BRD9–UCEC (DFS)

Open the UCEC breakdown →